OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
June 03, 2021
Celltrion Healthcare has revealed positive one-year results from a Phase III trial comparing biosimilar adalimumab, Yuflyma, with the reference adalimumab in patients with rheumatoid arthritis.
May 18, 2021
The US Supreme Court has denied a petition by Sandoz, a Novartis company, to review a July 2020 ruling concerning its biosimilar Erelzi (etanercept-szzs), blocking the company from launching the product.
May 07, 2021
Sandoz will soon begin enrolling patients with neovascular age-related macular degeneration in a Phase III study with its proposed biosimilar to aflibercept.
February 17, 2021
The EC has granted marketing authorization to Celltrion Healthcare for its adalimumab biosimilar, Yuflyma (CT-P17).
August 13, 2020
The company has launched its biosimilar rituximab, Ritucad, for the Indian market.
The companies received approval from the EC for Zercepac (HLX02), a biosimilar referencing Roche’s originator biologic, Herceptin (trastuzumab).
The committee has given a positive opinion on the biosimilar bevacizumab for several cancer indications.
August 05, 2020
The use of analytical assays is crucial for determining that biosimilar critical quality attributes remain on point.
July 01, 2020
Appropriate analytical assays are needed to determine and ensure that biosimilar critical quality parameters are on track.
April 08, 2020
Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.